MapLight Therapeutics names Martin Babler, Troy Cox to board of directors
PUBT · 06/24 11:01
Share
Listen to the news
- MapLight Therapeutics added Martin Babler and Troy Cox to its board following their election at the June 23 annual meeting.
- Babler, CEO and chairman of Alumis since September 2021, joined the audit committee; he previously led Principia Biopharma.
- Cox, former Foundation Medicine CEO (2017-2019), became chair of the nominating and corporate governance committee; he previously held senior roles at Genentech.
- They replaced Robert Malenka and Jim Trenkle, who did not stand for re-election and have left the board.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606240700PRIMZONEFULLFEED9751749) on June 24, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved